PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD THURSDAY, MAY 9, 2024
This Proxy Statement, along with the accompanying Notice of Annual Meeting of Stockholders, contains information about the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of TruBridge, Inc., including any adjournments or postponements of the Annual Meeting. We are holding the Annual Meeting on Thursday, May 9, 2024 at 8:00 a.m., Central Time, in a virtual meeting format only via the Internet. Stockholders may participate in and vote and submit questions during the Annual Meeting via the Internet at www.proxydocs.com/TBRG. In order to attend, you must register in advance at www.proxydocs.com/TBRG. You will need the control number included on your Notice of Internet Availability of Proxy Materials or proxy card if you request a hard copy of the proxy materials.
This Proxy Statement relates to the solicitation of proxies by our Board of Directors (the “Board” or “Board of Directors”) for use at the Annual Meeting.
On or about March 27, 2024, we began sending a Notice of Internet Availability of Proxy Materials to all stockholders entitled to vote at the Annual Meeting.
We encourage all of our stockholders to vote prior to or during the Annual Meeting, and we hope the information contained in this document will help you decide how you wish to vote.
On March 4, 2024, we changed our name from Computer Programs and Systems, Inc. to TruBridge, Inc. and our ticker was changed to “TBRG.” In this Proxy Statement, the terms “TruBridge,” “the Company,” “we,” “us” and “our” refer to TruBridge, Inc. following the name change and Computer Programs and Systems, Inc. prior to the name change.
Important Notice Regarding the Availability of Proxy Materials for the
Annual Meeting of Stockholders to be held on May 9, 2024
The Notice of Annual Meeting of Stockholders, the Proxy Statement and the Company’s 2023 Annual Report to Stockholders are available free of charge to view, print and download at www.proxydocs.com/TBRG.
Additionally, you can find a copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including financial statements and schedules thereto, on the website of the Securities and Exchange Commission, or the SEC, at www.sec.gov, or in the “Corporate Information” section of our website at http://investors.trubridge.com (under the “2024 Annual Meeting Materials” link). You may also obtain a printed copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including financial statements and schedules thereto, free of charge, from us by sending a written request to: TruBridge, Inc., 54 St. Emanuel Street, Mobile, Alabama 36602, Attn: Corporate Secretary. Exhibits will be provided upon written request and payment of an appropriate processing fee.
1
What is the Board’s voting recommendation?
The Company’s Board of Directors recommends that you vote your shares FOR the election of the Class I director nominees set forth in this Proxy Statement; FOR the approval, on an advisory basis, of the compensation of our NEOs; and FOR the ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accountants for the year ending December 31, 2024.
Unless instructed to the contrary, the shares represented by the proxies will be voted FOR the listed nominees in Proposal 1, FOR Proposal 2, and FOR Proposal 3.
What shares owned by me can be voted?
All shares owned by you as of the close of business on March 15, 2024 (the “Record Date”) may be voted. You may cast one vote per share of common stock that you held on the Record Date. These include shares that are: (1) held directly in your name as the stockholder of record, and (2) held for you as the beneficial owner through a broker, bank or other nominee. At the close of business on the Record Date, there were 14,652,956 shares of the common stock of the Company, par value $0.001 per share, outstanding. Each stockholder is entitled to one vote in person or by proxy for each share of common stock held on all matters properly to come before the Annual Meeting.
What is the difference between holding shares as a stockholder of record and as a beneficial owner?
Most of the Company’s stockholders hold their shares through a broker, bank or other nominee rather than directly in their own name. As summarized below, there are some differences between shares held of record and those owned beneficially.
Stockholder of Record
If your shares are registered directly in your name with the Company’s transfer agent, Computershare Inc., you are considered the stockholder of record with respect to those shares, and the Notice is being sent directly to you. As the stockholder of record, you have the right to grant your voting proxy directly to the persons named as proxy holders, Christopher L. Fowler, the Company’s President and Chief Executive Officer, and Vinay Bassi, the Company’s Chief Financial Officer, Secretary and Treasurer, or to vote during the Annual Meeting. If you request printed copies of the proxy materials, the Company will provide a proxy card for you to use. You may also vote by Internet or telephone, as described below under the heading “How can I vote my shares without participating in the Annual Meeting?”
Beneficial Owner
If your shares are held in a stock brokerage account or by a bank or other nominee, you are considered the beneficial owner of shares held in “street name,” and these proxy materials are being forwarded to you by your broker, bank or other nominee who is considered, with respect to those shares, the stockholder of record. As the beneficial owner, you are invited to participate in the Annual Meeting. You also have the right to direct your broker, bank or other nominee on how to vote these shares. The Notice or voting instruction form that you receive should include instructions for you to direct your broker, bank or other nominee how to vote your shares. You may also vote by Internet or telephone, as described below under “How can I vote my shares without participating in the Annual Meeting?” However, shares held in “street name” may be voted during the meeting by you only if you obtain a signed proxy from the record holder (broker, bank or other nominee) giving you the right to vote the shares.
How can I participate in the Annual Meeting?
In order to allow our stockholders and other attendees to participate from any location and to reduce the environmental impact of our Annual Meeting, we have determined that the Annual Meeting will be held in a virtual meeting format only via the Internet. You may participate in and vote and submit questions during the Annual Meeting via the Internet at www.proxydocs.com/TBRG.
In order to attend the Annual Meeting, you must register in advance at www.proxydocs.com/TBRG. In order to register, you will need the control number included on your Notice or proxy card if you request a hard copy of the proxy materials. Upon completing your registration, you will receive further instructions via email, including information about when you should expect to receive your unique link that will allow you access to the meeting and to vote and submit questions during the meeting. Please be sure to follow the instructions found on your proxy card and/or voting instruction form and subsequent instructions that will be delivered to you via email.
3
Mr. Fowler has been employed by TruBridge for more than 20 years in a number of positions and areas and has served in senior executive positions for over 10 years, including as Chief Operating Officer and now as Chief Executive Officer, providing him with intimate knowledge of our operations and the healthcare industry.
Denise W. Warren was first elected as a director in November 2017. Ms. Warren served as the Executive Vice President and Chief Operating Officer of WakeMed Health and Hospitals, a 919-bed healthcare system with multiple facilities in the Raleigh, North Carolina area, from 2015 until her retirement effective December 31, 2020. Prior to this, Ms. Warren served as the Chief Financial Officer of Capella Healthcare, Inc. from 2005 to 2015. Ms. Warren began her career in 1980 with Ernst & Whinney (Ernst & Young), and then worked for a series of financial firms, including E. F. Hutton, Ford Capital, LTD, CS First Boston and Merrill Lynch & Co. Before joining Capella Healthcare, Inc., Ms. Warren served as Senior Vice President and Chief Financial Officer of Gaylord Entertainment Company and Senior Equity Analyst and Research Director for Avondale Partners LLC. She currently serves as a member of the board of directors and the compensation committee, as well as the chairperson of the audit committee, for Brookdale Senior Living, Inc. (a NYSE-traded company). She also serves on the board of directors, and as the chairperson of the audit committee, for Virtusa, Inc., Straive and Newport Healthcare. Additionally, she serves as a director for Carteret County Community Foundation. Ms. Warren previously served on the boards of directors of HeartCare+ and CancerCare+, two collaborations with Duke University Health System, Rockroom Insurance Group, the Raleigh Chamber of Commerce, the American Heart Association—Middle Tennessee, and the Federation of American Hospitals; and served on the Vizient Central Atlantic Executive Board. Ms. Warren is National Association of Corporate Directors (NACD) Directorship Certified™. The NACD Directorship Certification™ program equips directors with the foundation of knowledge sought by boards to effectively contribute in the boardroom. NACD Directorship Certified directors establish themselves as committed to continuing education on emerging issues and to helping to elevate the profession of directorship. In 2020, Ms. Warren also received the Corporate Director’s Certificate from the Harvard Business School.
Ms. Warren brings more than 30 years of experience in operations, finance and executive management and has an extensive track record working with both public and private companies. The Board believes that Ms. Warren’s financial and accounting expertise and her substantial advisory experience in the healthcare industry make her a valuable asset to the Board.
Class III Continuing Directors – Terms to Expire in 2026
Regina M. Benjamin was first elected as a director in November 2017. Dr. Benjamin served as the 18th United States Surgeon General and Vice Admiral of the U.S. Public Health Service from 2009 to 2013, and currently serves as the Chief Executive Officer of BayouClinic, Inc., which she founded in 1990. In 1995, Dr. Benjamin became the first person under age 40 elected to the American Medical Association Board of Trustees, and in 2004, she became President of the Medical Association of Alabama, making her the first African American female president of a state medical society in the nation. Dr. Benjamin is currently a member of the board of directors and audit committee of Doximity, Inc. (a NYSE-traded company). She also serves as an independent director of Professional Disposables International Inc., Kaiser Foundation Hospitals and Health Plan, Ascension Health Alliance, and Everly Health. Dr. Benjamin previously served on the boards of directors of Oak Street Health, Inc. (a NYSE-traded company), ConvaTec (a London Stock Exchange-traded company), Diplomat Pharmacy, Inc. and Alere Inc. (a NYSE-traded company).
Dr. Benjamin has substantial experience in the healthcare industry and has a deep understanding of the medical community and the dynamic regulatory and reimbursement environment. She has extensive expertise providing leadership in regulatory and compliance affairs to both public and private companies in the healthcare industry, which makes Dr. Benjamin a valuable asset to the Board.
David A. Dye has been a director since March 2002 and was appointed as Chief Operating Officer effective October 10, 2022, transitioning from his role as Chief Growth Officer to which he was appointed in November 2015. Mr. Dye served as Chairperson of the Board of Directors from May 2006 until April 2019, and as our Chief Financial Officer, Secretary and Treasurer from June 2010 until November 2015. Mr. Dye began his career with the Company in May 1990 as a Financial Software Support Representative. From that time until June 1999, he worked for the Company in various capacities, including as Manager of Financial Software Support, Director of Information Technology and then as our Vice President supervising the areas of sales, marketing and information technology. Mr. Dye served as the Company’s President and Chief Executive Officer from July 1999 until May 2006, at which time he was appointed Chairperson of the Board. Mr. Dye served as a director of Bulow Biotech Prosthetics, a company headquartered in Nashville, Tennessee that operates prosthetic clinics in the Southeastern United States from July 2006 until October 2018.
Mr. Dye has been employed by TruBridge for more than 30 years in a number of positions and areas and has served in senior executive positions for over 20 years, including as Chief Executive Officer for over six years, Chief Financial Officer for over five years and now as Chief Operating Officer, providing him with extensive knowledge of our operations.
10
|
|
|
|
|
|
|
Focus on outcomes: The Nominating and Corporate Governance Committee discusses the outcomes of the Board and committee evaluations, determines appropriate follow-up action items and assigns responsibility for such actions. |
As a result of the 2023 evaluation process, the Board discussed strategic adjustments to the Board’s composition and committee assignments, potential continued improvements to the materials and information that the directors receive from management throughout the year, and a desire to increase engagement with various subject-matter experts on the management team. The Nominating and Corporate Governance Committee is responsible for ensuring these action items, as well as others resulting from the evaluation process, are implemented throughout the year.
Governance and Compliance Documents and Training
The Board of Directors has adopted Corporate Governance Guidelines that set forth the Company’s fundamental corporate governance principles and provide a flexible framework for the governance of the Company. The Corporate Governance Guidelines address, among other things, Board functions and responsibilities, management succession, Board membership and independence, Board meetings and Board committees, access to management, director orientation and continuing education, and annual performance evaluations, as discussed above under “Board, Committee and Individual Director Evaluation Program.” The Nominating and Corporate Governance Committee regularly reviews and reassesses the adequacy of the Corporate Governance Guidelines and recommends any proposed changes to the Board, and the full Board approves such changes as it deems appropriate.
We have adopted a Code of Business Conduct and Ethics that is applicable to all of our directors, officers (including our CEO and senior financial officers) and employees and management conducts random audits to test compliance with the Code. We have also adopted a separate Code of Ethics with additional guidelines and responsibilities applicable to our CEO and senior financial officers, known as the Code of Ethics for CEO and Senior Financial Officers. Our Codes of Ethics are closely tied to our other compliance documents, including our Anti-Corruption Policy and our Gifts, Meals, Entertainment, and Travel Policy, which the Board of Directors adopted in 2019. We have international operations, and as such compliance with all anti-corruption and anti-bribery laws is a key component of our ethics focus. In accordance with applicable laws, we prohibit improperly influencing business decisions or improperly securing advantages. Our compliance team conducts regular compliance training for our directors and annual compliance training for certain employees, and this dedication helps to ensure that our personnel are aware of their compliance obligations and well-equipped to meet them.
In 2022, we adopted a Human Rights Statement and a Vendor Code of Conduct and the Board oversees our compliance with these policies. The Human Rights Statement sets forth the Company’s commitment to promoting the protection of human rights through its business dealings and treating customers, employees and vendors with dignity. The Vendor Code of Conduct establishes minimum standards that must be met by all manufacturers, distributors, vendors and other suppliers regarding their treatment of workers, workplace safety and ethical business practices.
Our compliance team has developed and implemented a number of internal policies and procedures related to medical billing and coding compliance activity. These policies and procedures address, among other topics, customers’ external auditing activity, Medicare Credit Balance identification, timely resolution, reporting and internal auditing of these matters. Periodically, the directors receive in-depth education on the elements of an effective medical billing and coding compliance program, as well as their compliance oversight responsibilities.
Copies of these documents and policies are available on our website at http://investors.trubridge.com under “Corporate Governance.”
Director Independence
Nasdaq listing standards require that the Company have a majority of independent directors. Accordingly, because our Board of Directors currently has eight members, Nasdaq requires that five or more of the directors be independent. At the conclusion of the Annual Meeting, the Board will have seven members, so four or more of the directors must be independent. Nasdaq’s listing standards provide that no director will qualify as “independent” for these purposes unless the Board of Directors affirmatively determines that the director has no relationship with the Company that would interfere with the exercise of the director’s independent judgment in carrying out the responsibilities of a director. Additionally, the listing standards set forth a list of relationships that would preclude a finding of independence.
The Board affirmatively determines the independence of each director and nominee for election as a director. The Board makes this determination annually. In accordance with Nasdaq’s listing standards, we do not consider a director to be
13
independent unless the Board determines (i) that no relationship exists that would preclude a finding of independence under Nasdaq’s listing standards and (ii) that the director has no relationship with the Company (either directly or as a partner, stockholder or officer of an organization that has a relationship with the Company) that would interfere with the exercise of the director’s independent judgment in carrying out his or her responsibilities as a director. Members of the Audit, Compensation and Nominating and Corporate Governance Committees must also meet applicable independence tests of Nasdaq and the SEC. Pursuant to the charter of the Innovation and Technology Committee of the Board, the members of such committee must also qualify as independent under Nasdaq’s listing standards.
The Board of Directors has reviewed a summary of directors’ responses to a questionnaire asking about their relationships with the Company, as well as material provided by management related to transactions, relationships or arrangements between the Company and the directors and parties related to the directors. Following this review, the Board determined that all five of the non-employee directors are independent. Additionally, the Board determined that each current member of the Audit, Compensation, Nominating and Corporate Governance, and Innovation and Technology Committees, as well as each director who served on any of the committees during 2023, also satisfies the independence tests referenced above.
Company Leadership Structure
The business of the Company is managed under the direction of the Board of Directors, which is elected by our stockholders. The basic responsibility of the Board is to lead the Company by exercising its business judgment to act in what each director reasonably believes to be the best interests of the Company and its stockholders. The Board oversees the business and affairs of the Company and monitors the performance of its management. Although the Board is not involved in the Company’s day-to-day operations, the directors keep themselves informed about the Company through meetings of the Board, reports from management and discussions with the Company’s NEOs. Directors also communicate with the Company’s outside advisors, as necessary.
The Board does not have a policy requiring the separation or combination of the CEO and Chairperson roles, but these positions have been separated since the Company’s initial public offering in 2002. In February 2019, the Board elected Glenn P. Tobin, an independent director, as the Chairperson of the Board, effective as of the 2019 Annual Meeting. The Board has determined that it is in the best interests of the Company’s stockholders at this time to have an independent director serve as Chairperson of the Board. The Board believes this leadership structure effectively allocates authority, responsibility and oversight between management and the independent members of our Board. It gives primary responsibility for the operational leadership and strategic direction of the Company to our CEO, while the Chairperson facilitates our Board’s independent oversight of management, promotes communication between senior management and our Board about issues such as executive compensation, company performance, and management development and succession planning, and leads our Board’s consideration of key governance matters. As the Chairperson, Mr. Tobin presides at all meetings of the Board, including executive sessions of the independent directors, sets the agendas for Board meetings in consultation with the CEO and other directors, communicates the Board’s feedback to the CEO and communicates on behalf of the Board with various constituencies involved with the Company. In the event that the Chairperson of the Board is not independent, the Board can elect an independent director to serve in a lead capacity to coordinate the activities of the other independent directors and to perform such other duties and responsibilities as set forth in the Lead Director Charter.
Executive Sessions
Executive sessions of the independent directors of the Board of Directors are to be held following each regular quarterly Board meeting and otherwise as needed. Such sessions are chaired by the Chairperson of the Board, if such individual is independent under Nasdaq’s listing standards, by the lead independent director, if the Chairperson is not independent, or in the absence of an independent Chairperson or a lead independent director, by an independent director selected by a majority of the independent directors. The chairperson of the executive sessions also establishes agendas for such sessions.
Risk Oversight
Our management continually monitors the material risks facing the Company, including financial risk, strategic risk, operational risk, and legal and compliance risk. The Board of Directors is responsible for exercising oversight of management’s identification and management of, and planning for, those risks. The Board believes that an effective risk management system should be focused on (1) timely identifying the material risks that the Company faces, (2) communicating necessary information with respect to material risks to senior executives and, as appropriate, to the Board or relevant Board committee, (3) implementing appropriate and responsive risk management strategies consistent with the Company’s risk profile, and (4) integrating risk management into Company decision-making.
14
Employment and Other Arrangements
Employment Agreement with Mr. Fowler. On July 1, 2022, the Company entered into an employment agreement with Mr. Fowler (the “Employment Agreement”), concurrently with his appointment as the Company’s President and Chief Executive Officer. The Employment Agreement provided for an initial annual base salary of $600,000 and provides that Mr. Fowler is eligible to receive an annual bonus. Mr. Fowler is eligible to participate in the 2019 Incentive Plan and is entitled to participate in all employee benefit plans, practices, and programs maintained by the Company, as in effect from time to time, on a basis which is no less favorable than is provided to other similarly situated executives of the Company, to the extent consistent with applicable law and the terms of the applicable plans.
The Employment Agreement may be terminated by either party at any time and for any reason upon thirty (30) days’ advance written notice. Under the terms of the Employment Agreement, Mr. Fowler is eligible for specified termination payments and benefits in the event of a termination of Mr. Fowler’s employment (i) due to his death or disability, (ii) by Mr. Fowler without good reason, by the Company for cause, or upon a non-renewal of the Employment Agreement by Mr. Fowler, (iii) by Mr. Fowler for good reason, by the Company without cause, or upon a non-renewal of the Employment Agreement by the Company, or (iv) by Mr. Fowler for good reason, by the Company without cause, or upon a non-renewal of the Employment Agreement by the Company within twelve (12) months following a change of control of the Company, subject to his execution and non-revocation of a release of claims in the Company’s favor and his compliance with confidentiality, non-competition, non-solicitation, non-disparagement and other covenants, all as more specifically provided for in the Employment Agreement and described below under “Potential Payments Upon Termination or Change in Control.” The Company believes that the severance payments and benefits payable under the Employment Agreement are consistent with industry practice.
Executive Severance Agreements with Certain Executive Officers. Between June 20, 2023 and June 23, 2023, the Company entered into an Executive Severance Agreement (the “Severance Agreement”) with each of Mr. Chambless, Mr. Dye, Ms. Severance and Mr. Cronkite, as well as other members of the Company’s senior management team (each, an “Executive”). The purposes of the Severance Agreements are to standardize the compensation arrangements among the Company’s senior management team and to aid in the Company’s attraction and retention of executive-level talent, as well as to enhance protections for the Company in connection with executive transitions. Under the Severance Agreement, in the event the Executive is terminated by the Company without “Cause” (as defined in the Severance Agreement), other than within 12 months following a “Change in Control” (as defined in the Severance Agreement) of the Company, the Executive will be eligible to receive, in addition to any accrued but unpaid amounts or benefits, (i) 12 months (18 months, in the case of Mr. Dye) of equal installment payments which are in the aggregate equal to 1 times (1.5 times, in the case of Mr. Dye) the sum of the Executive’s base salary and target bonus for the year in which the termination event occurs; (ii) up to 12 months (18 months, in the case of Mr. Dye) of reimbursements for medical and/or dental continuation coverage; (iii) continued vesting of the Executive’s outstanding unvested shares of restricted stock during the period in which the Executive is subject to non-competition and non-solicitation covenants; and (iv) a pro rata portion of the Executive’s outstanding cash incentive awards and performance share awards to be calculated in the manner set forth in the applicable award agreements based on the degree of attainment of the applicable performance goals at the end of the applicable performance period, with the amount of the awards, if any, to be pro-rated based on the number of days that the Executive was employed by the Company during the performance period.
The Severance Agreement further provides that, in the event the Executive is terminated by the Company without Cause within 12 months following a Change in Control of the Company, the Executive will be eligible to receive, in addition to any accrued but unpaid amounts or benefits, (i) a lump sum payment equal to one and 1.5 times (2 times, in the case of Mr. Dye) the sum of the Executive’s base salary and target bonus for the year in which the termination event occurs; and (ii) up to 12 months (18 months, in the case of Mr. Dye) of reimbursements for medical and/or dental continuation coverage.
The Executive’s receipt of severance payments and benefits is subject to the Executive’s execution and non-revocation of a release of claims in the Company’s favor and compliance with confidentiality, non-disparagement and other covenants, all as more specifically provided for in the Severance Agreement. Additionally, the Executive’s receipt of severance payments and benefits is subject to the Executive’s compliance with non-competition and non-solicitation covenants for 12 months (18 months, in the case of Mr. Dye) following the termination event.
Perquisites and Other Benefits
None of our executive officers receive any perquisites. Our policy is to not provide perquisites to executives, in part because we believe that they do not effectively incentivize management to improve the financial performance of the Company. Additionally, we do not maintain any pension or defined benefit plans for the benefit of our executive officers.
33
Our executive officers, including the NEOs, are eligible to participate in the Company’s 401(k) plan on the same terms as all of our employees. The plan allows eligible employees to contribute up to 60% of their pre-tax earnings up to the statutory limit prescribed by the Internal Revenue Service. The Company matches a discretionary amount determined by the Board of Directors. In 2023, we matched employee contributions up to $2,000 per employee. Our executive officers, including the NEOs, also participate in our other benefit plans on the same terms as our other employees. These plans include medical and dental insurance, life insurance and long-term disability insurance.
Recoupment Policy
Time-based restricted stock awards, performance-based cash bonus awards and performance-based share awards granted under the Plans are subject to recovery or adjustment by the Company as may be required pursuant to any law, government regulation or stock exchange listing requirement (or any policy adopted by the Company pursuant to any such law, government regulation or stock exchange listing requirement).
In October 2023, we adopted a Policy for the Recovery of Erroneously Awarded Compensation (the “Clawback Policy”), in compliance with the requirements of the Dodd-Frank Act, final SEC rules and applicable Nasdaq listing standards, which covers our current and former officers subject to Section 16 of the Exchange Act, including all of our NEOs. Under the Clawback Policy, if there is a restatement of our financial results, the Company will recover erroneously awarded incentive compensation from such officers during a three-year lookback period.
Prohibition on Pledging and Hedging of Company Stock and Equity Award Repricing
The Company’s Insider Trading Policy (the “Policy”) prohibits the directors, officers and employees of the Company and any of its subsidiaries from pledging their common stock in the Company as security or engaging in transactions designed to “hedge” against the price of the Company’s common stock. The Policy explicitly prohibits short sales and hedging or monetization transactions, including options trading (buying or selling puts or calls or other derivative securities). These restrictions ensure that the NEOs, as well as other Company personnel, cannot offset or hedge against declines in the price of the Company’s common stock they own or have a personal interest in the price of their shares that may be different from the interests of other stockholders generally. None of the Company’s directors or executive officers currently engage in any pledging or hedging transactions.
The Board of Directors and the Compensation Committee view equity-based compensation to be a key factor in incentivizing the future performance of our executives. Consequently, the 2019 Incentive Plan provides that the Compensation Committee is not permitted to reduce the exercise price of outstanding stock options or stock appreciation rights; replace any stock option or stock appreciation right with a new award with a lower exercise price; cancel any stock option or stock appreciation right in exchange for cash; or take any other action that would be treated as a repricing under the Nasdaq listing rules.
Equity Ownership and Retention Requirements for Executive Officers
The Board of Directors has always encouraged the Company’s executive officers to have a financial stake in the Company, and the officers have generally owned shares of our common stock. Under the current stock ownership policy, the Chief Executive Officer should acquire and beneficially own shares of the Company’s common stock valued at five (5) times such individual’s annual base salary. Each other executive officer should acquire and beneficially own shares of the Company’s common stock valued at two (2) times such individual’s annual base salary. Current executive officers have five years from the date of his or her designation by the Board as an executive officer to satisfy this guideline. Additionally, officers are required to retain 100% of the net shares (as defined in the amended Corporate Governance Guidelines) obtained through the Company’s equity plans beginning on the one-year anniversary of the date of his or her designation by the Board as an executive officer until the stock ownership guidelines are achieved. All of the Company’s executive officers currently satisfy the stock ownership guidelines, consistent with the applicable time periods the executive officers have to achieve the required ownership levels. The Corporate Governance Guidelines contain these requirements and are available on our website at http://investors.trubridge.com under “Corporate Governance.”
As with the stock ownership guidelines for the Company’s non-employee directors, the minimum number of shares to be held by an executive officer will be calculated on the first trading day of each calendar year based on the fair market value of such shares (a “Determination Date”). Any subsequent change in the value of the shares will not affect the amount of stock executive officers should hold during that year. For purposes of meeting the ownership guidelines, the following categories of stock are counted: (i) shares owned directly, (ii) shares owned indirectly (e.g., by a spouse, minor children or a trust), and (iii) time-based restricted stock. However, unexercised stock options and unearned performance shares, if any, are not counted toward meeting the guidelines. If the number of shares that an executive officer should own is increased as a result of an
34
such a termination event also include eighteen (18) months of COBRA reimbursements, as detailed above. Finally, the cash payments due to Mr. Fowler upon such a termination event also include the actual performance-based cash bonus that he received for the 2023 performance period.
In the event of such a termination for a NEO other than Mr. Fowler, pursuant to each NEO’s severance agreement, the NEO would be entitled to a lump sum payment equal to one and one-half (11⁄2) times (two (2) times in the case of Mr. Dye) the sum of the NEO’s base salary and target bonus for the year in which the termination event occurred, payable within seventy (70) days following the termination date. The cash payments due to these NEOs would also include up to twelve (12) months (eighteen (18) months, in the case of Mr. Dye) of COBRA reimbursements, as detailed above. Finally, the cash payments due to each NEO upon such a termination event also include the actual performance-based cash bonus that such NEO received for the 2023 performance period.
(2) |
Accelerated Vesting of Unvested Restricted Stock: |
Termination by the Company Without Cause. Pursuant to Mr. Fowler’s employment agreement and the other NEOs’ severance agreements, the amounts presented in this column for NEO upon such a termination event reflect the value of the continued vesting of unvested shares of restricted stock for eighteen (18) months (twelve (12) months in the case of Ms. Severance and Mr. Cronkite) following such termination, during which time the NEO would be subject to certain restrictive covenants as set forth in his or her employment agreement or severance agreement, as applicable.
Termination by the NEO for Good Reason. Pursuant to Mr. Fowler’s employment agreement, the amounts presented in this column for Mr. Fowler upon such a termination event reflect the value of the continued vesting of unvested shares of restricted stock for eighteen (18) months following such termination, during which time he would be subject to certain restrictive covenants as set forth in his employment agreement. The other NEOs are not entitled to continued vesting of unvested restricted stock in connection with a Termination by the NEO for Good Reason.
Termination Due to Death or Disability. Pursuant to Mr. Fowler’s employment agreement, upon such a termination event, the treatment of his outstanding equity awards would be determined in accordance with the 2019 Incentive Plan and the applicable award agreements. In the event of such a termination, each NEO (including Mr. Fowler) would be entitled to accelerated vesting of all unvested restricted stock.
Change in Control. Neither Mr. Fowler nor any other NEO is entitled to any accelerated vesting of outstanding equity in the event of a Change in Control under Mr. Fowler’s employment agreement or the other NEOs’ severance agreements, respectively. However, pursuant to the award agreements governing the outstanding time-based restricted stock awards, each NEO (including Mr. Fowler) would be entitled to accelerated vesting of all unvested restricted stock.
Termination by the Company Without Cause or by the NEO for Good Reason in connection with a Change in Control. Pursuant to Mr. Fowler’s employment agreement, upon such a termination event, the treatment of his outstanding equity awards would be determined in accordance with the 2019 Incentive Plan and the applicable award agreements. Pursuant to the award agreements governing the time-based restricted stock awards, each NEO (including Mr. Fowler) would have received accelerated vesting of all unvested restricted stock upon the Change in Control, as described above.
These values have been determined based on the closing price of the Company’s common stock on NASDAQ on December 29, 2023, the last trading day of 2023 ($11.20), multiplied by the number of applicable shares.
(3) |
Accelerated Issuance of Unearned PSAs: |
Termination by the Company Without Cause. Pursuant to his employment agreement, the amounts presented in this column for Mr. Fowler upon such a termination event reflect a pro rata portion of his outstanding performance share awards based on the actual attainment of performance goals. The amounts reported in the table for the Three-Year PSAs granted in 2021 (the “2021 PSAs”) that would have been earned in the event of a termination of employment that occurred on December 31, 2023 are based on the product of (y) the actual number of 2021 PSAs earned by Mr. Fowler and (z) our closing stock price of $11.20 on December 29, 2023. The amounts reported in the table for the Three-Year PSAs granted in 2022 or 2023 (the “Ongoing PSAs”) that would have been earned in the event of a termination of employment that occurred on December 31, 2023 assume that the Ongoing PSAs would be earned at the target level of achievement and are based on the product of (x) the target number of Ongoing PSAs granted to Mr. Fowler in 2022 or 2023, as applicable, (y) our closing stock price of $11.20 on December 29, 2023 and (z) a fraction, the numerator of which equals the number of days that Mr. Fowler was employed during the performance period and the denominator of which equals the total number of days in the performance period. The foregoing calculations of the pro rata portion of outstanding performance share awards is hereinafter referred to as the “Pro Rata PSA Calculations.”
47
OTHER MATTERS
As of the date of this Proxy Statement, the Board does not know of any business which will be presented for consideration at the Annual Meeting other than that specified herein and in the Notice of Annual Meeting of Stockholders, but if other matters are properly presented, it is the intention of the persons designated as proxies to vote in accordance with their judgment on such matters.
DEADLINE FOR STOCKHOLDER PROPOSALS
In order for a proposal by a stockholder of the Company to be eligible to be included in the proxy statement and proxy form for the 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) pursuant to SEC Rule 14a-8, the proposal must be received by the Company’s Corporate Secretary at TruBridge, Inc., 54 St. Emanuel Street, Mobile, Alabama 36602, on or before November 27, 2024. If the date of the 2025 Annual Meeting changes by more than 30 days from May 9, 2025, then the deadline to submit stockholder proposals for inclusion in the proxy statement for the 2025 Annual Meeting will be a reasonable time before the Company begins to print and mail its proxy materials for the 2025 Annual Meeting. The Company will determine whether to include a proposal in the 2025 proxy statement in accordance with the SEC rules governing the solicitation of proxies.
If a stockholder proposal is submitted outside the proposal process mandated by SEC Rule 14a-8, and is submitted instead under the Company’s advance notice Bylaw provision (Section 1.13 of the Bylaws), the proposal must be received by the Company’s Corporate Secretary at TruBridge, Inc., 54 St. Emanuel Street, Mobile, Alabama 36602 not earlier than January 9, 2025 nor later than February 8, 2025, together with the necessary supporting documentation required under that Bylaw provision. If the date of the 2024 Annual Meeting is advanced by more than 30 days or is delayed by more than 70 days from May 9, 2025, then to be timely the nomination or proposal must be received by the Company no earlier than the 120th day prior to the 2025 Annual Meeting and no later than the close of business on the later of the 90th day prior to the meeting and the 10th day following the day on which public announcement of the date of the 2025 Annual Meeting is first made. In addition to satisfying the requirements under our Bylaws, to comply with the SEC’s universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees at the 2025 Annual Meeting must provide notice to the Company that complies with the informational requirements of Rule 14a-19 under the Exchange Act.
A COPY OF OUR 2023 ANNUAL REPORT TO STOCKHOLDERS, WHICH INCLUDES OUR FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES, IS ENCLOSED WITH THIS PROXY STATEMENT. IF THE ANNUAL REPORT IS NOT INCLUDED, PLEASE NOTIFY US IN WRITING AT TRUBRIDGE, INC., 54 ST. EMANUEL STREET, MOBILE, ALABAMA 36602, ATTN: CORPORATE SECRETARY.
HOUSEHOLDING OF PROXY MATERIALS
SEC rules permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements and notices with respect to two or more stockholders sharing the same address by delivering a single proxy statement or a single notice addressed to those stockholders. This process, which is commonly referred to as “householding,” provides cost savings for companies. Some brokers household proxy materials, delivering a single proxy statement to multiple stockholders sharing an address, unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement or notice, please notify your broker. You may also call the Broadridge Householding Election system at (866) 540-7095 or notify them in writing at Broadridge, Householding Department, 51 Mercedes Way, Edgewood, New York to decline or modify previous householding elections. You can also request prompt delivery of a copy of the proxy statement and annual report by sending a written request to TruBridge, Inc., 54 St. Emanuel Street, Mobile, Alabama 36602, Attn: Corporate Secretary or by calling the Company at (877) 424-1777.
64
Pay vs Performance Disclosure - USD ($)
|
6 Months Ended |
12 Months Ended |
Dec. 31, 2022 |
Jun. 30, 2022 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Pay vs Performance Disclosure |
|
|
|
|
|
|
Pay vs Performance Disclosure, Table |
|
|
In accordance with rules adopted by the SEC pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we are providing the following disclosure regarding executive compensation for our principal executive officers (“PEO”) and Non-PEO NEOs and Company performance for the fiscal years listed below. The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
2,306,789 |
|
|
|
— |
|
|
|
331,873 |
|
|
|
1,181,139 |
|
|
|
343,658 |
|
|
|
42.92 |
|
|
|
102.92 |
|
|
$ |
102.92 |
|
|
$ |
47,578 |
|
|
|
|
1,600,378 |
|
|
|
970,891 |
|
|
|
1,951,380 |
|
|
|
821,879 |
|
|
|
1,161,724 |
|
|
|
718,719 |
|
|
|
104.30 |
|
|
|
105.55 |
|
|
$ |
15,867 |
|
|
$ |
55,899 |
|
|
|
|
1,889,943 |
|
|
|
1,797,189 |
|
|
|
— |
|
|
|
— |
|
|
|
1,405,425 |
|
|
|
1,333,071 |
|
|
|
112.27 |
|
|
|
136.66 |
|
|
$ |
18,430 |
|
|
$ |
52,677 |
|
|
|
|
1,274,209 |
|
|
|
990,996 |
|
|
|
— |
|
|
|
— |
|
|
|
1,023,409 |
|
|
|
801,007 |
|
|
|
102.85 |
|
|
|
123.94 |
|
|
$ |
14,246 |
|
|
$ |
43,387 |
|
(1) |
J. Boyd Douglas was our PEO from May 17, 2006 to June 30, 2022. Christopher L. Fowler was our PEO from July 1, 2022 to present. The individuals comprising the Non-PEO NEOs for each year presented are listed below. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Matt J. Chambless |
|
Matt J. Chambless |
|
Matt J. Chambless |
|
Matt J. Chambless |
David A. Dye |
|
David A. Dye |
|
David A. Dye |
|
David A. Dye |
Christopher L. Fowler |
|
Christopher L. Fowler |
|
Dawn M. Severance |
|
Dawn M. Severance |
Troy D. Rosser |
|
Troy D. Rosser |
|
Amaris McComas |
|
Wes D. Cronkite |
|
|
|
|
Troy D. Rosser |
|
|
(2) |
The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below. |
(3) |
Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEOs and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards column are the totals from the Stock Awards column set forth in the Summary Compensation Table. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total for J. Boyd Douglas
|
|
|
|
|
|
|
|
|
|
|
2022 |
|
|
1,600,378 |
|
|
|
(738,338 |
) |
|
|
108,851 |
|
|
|
970,891 |
|
2021 |
|
|
1,889,943 |
|
|
|
(726,843 |
) |
|
|
634,089 |
|
|
|
1,797,189 |
|
2020 |
|
|
1,274,209 |
|
|
|
(632,366 |
) |
|
|
349,153 |
|
|
|
990,996 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2023 |
|
|
2,306,789 |
|
|
|
(1,625,994 |
) |
|
|
(348,922 |
) |
|
|
331,873 |
|
2022 |
|
|
1,951,380 |
|
|
|
(1,238,352 |
) |
|
|
108,851 |
|
|
|
821,879 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Awards for Non -PEO
|
|
|
Equity Values for Non- PEO
|
|
|
Actually Paid to Non- PEO
|
|
|
|
|
|
|
2023 |
|
|
1,181,139 |
|
|
|
(657,440 |
) |
|
|
(180,041 |
) |
|
|
343,658 |
|
2022 |
|
|
1,161,724 |
|
|
|
(526,478 |
) |
|
|
83,473 |
|
|
|
718,719 |
|
2021 |
|
|
1,405,425 |
|
|
|
(629,160 |
) |
|
|
556,806 |
|
|
|
1,333,071 |
|
2020 |
|
|
1,023,409 |
|
|
|
(529,008 |
) |
|
|
306,606 |
|
|
|
801,007 |
| The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2022 |
|
219,856 |
|
|
(159,850 |
) |
|
|
0 |
|
|
|
48,845 |
|
|
|
0 |
|
|
|
0 |
|
|
|
108,851 |
|
2021 |
|
699,890 |
|
|
(89,049 |
) |
|
|
0 |
|
|
|
23,248 |
|
|
|
0 |
|
|
|
0 |
|
|
|
634,089 |
|
2020 |
|
381,626 |
|
|
11,187 |
|
|
|
0 |
|
|
|
(43,660 |
) |
|
|
0 |
|
|
|
0 |
|
|
|
349,153 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2023 |
|
|
239,478 |
|
|
|
(298,292 |
) |
|
|
0 |
|
|
|
8,236 |
|
|
|
(298,344 |
) |
|
|
0 |
|
|
|
(348,922 |
) |
2022 |
|
|
219,856 |
|
|
|
(159,850 |
) |
|
|
0 |
|
|
|
48,845 |
|
|
|
0 |
|
|
|
0 |
|
|
|
108,851 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year |
|
Fair Value
of Equity
Awards
Granted During
Year That
Remained
Unvested as of
Last Day of
Year for
($) |
|
|
Average
Change in Fair
Value from
Last Day of
Prior Year to
Last Day of
Year of
Unvested
Equity Awards
NEOs
($) |
|
|
Average
Vesting-Date
Fair Value of
Equity
Awards
Granted
During Year
that Vested
During Year
for
NEOs
($) |
|
|
Average Change
in Fair Value
from Last Day
of Prior Year to
Vesting Date of
Awards that
Vested During
Year for
($) |
|
|
Average Fair
Value at Last
Day of Prior
Year of
Equity
Awards
Forfeited
During Year
NEOs
($) |
|
|
Average Value
of Dividends
or Other
Earnings Paid
on Equity
Awards Not
Otherwise
Included for
NEOs
($) |
|
|
Total -
Average
Inclusion of
Equity
Values for
NEOs
($) |
|
|
|
|
|
|
|
|
|
2023 |
|
|
96,827 |
|
|
|
(111,716 |
) |
|
|
0 |
|
|
|
11,610 |
|
|
|
(176,762 |
) |
|
|
0 |
|
|
|
(180,041 |
) |
2022 |
|
|
156,771 |
|
|
|
(101,887 |
) |
|
|
0 |
|
|
|
28,589 |
|
|
|
0 |
|
|
|
0 |
|
|
|
83,473 |
|
2021 |
|
|
605,829 |
|
|
|
(76,579 |
) |
|
|
0 |
|
|
|
27,556 |
|
|
|
0 |
|
|
|
0 |
|
|
|
556,806 |
|
2020 |
|
|
333,411 |
|
|
|
10,833 |
|
|
|
0 |
|
|
|
(37,638 |
) |
|
|
0 |
|
|
|
0 |
|
|
|
306,606 |
|
(4) |
The Peer Group TSR set forth in this table utilizes the S&P 600 Health Care Equipment & Services (Industry Group) (“S&P 600 Health Care Equipment & Services”), which we also utilize in the stock performance graph required by Item |
|
201(e) of Regulation S-K included in our Annual Report on Form 10-K for the year ended December 31, 2023. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year, in the Company and in the S&P 600 Health Care Equipment & Services, respectively. Historical stock performance is not necessarily indicative of future stock performance. |
(5) |
The Company selected Adjusted EBITDA as the most important financial measure it used to link Company performance to Compensation Actually Paid to our PEOs and Non-PEO NEOs in 2023. This performance measure may not have been the most important financial performance measure for years 2022, 2021 or 2020, and we may determine a different financial performance measure to be the most important financial performance measure in future years. See “Tabular List of Most Important Financial Performance Measures” below for the definition of Adjusted EBITDA. |
|
|
|
|
Company Selected Measure Name |
|
|
Adjusted EBITDA
|
|
|
|
Named Executive Officers, Footnote |
|
|
(1) |
J. Boyd Douglas was our PEO from May 17, 2006 to June 30, 2022. Christopher L. Fowler was our PEO from July 1, 2022 to present. The individuals comprising the Non-PEO NEOs for each year presented are listed below. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Matt J. Chambless |
|
Matt J. Chambless |
|
Matt J. Chambless |
|
Matt J. Chambless |
David A. Dye |
|
David A. Dye |
|
David A. Dye |
|
David A. Dye |
Christopher L. Fowler |
|
Christopher L. Fowler |
|
Dawn M. Severance |
|
Dawn M. Severance |
Troy D. Rosser |
|
Troy D. Rosser |
|
Amaris McComas |
|
Wes D. Cronkite |
|
|
|
|
Troy D. Rosser |
|
|
|
|
|
|
Peer Group Issuers, Footnote |
|
|
(4) |
The Peer Group TSR set forth in this table utilizes the S&P 600 Health Care Equipment & Services (Industry Group) (“S&P 600 Health Care Equipment & Services”), which we also utilize in the stock performance graph required by Item |
|
201(e) of Regulation S-K included in our Annual Report on Form 10-K for the year ended December 31, 2023. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year, in the Company and in the S&P 600 Health Care Equipment & Services, respectively. Historical stock performance is not necessarily indicative of future stock performance. |
|
|
|
|
Adjustment To PEO Compensation, Footnote |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total for J. Boyd Douglas
|
|
|
|
|
|
|
|
|
|
|
2022 |
|
|
1,600,378 |
|
|
|
(738,338 |
) |
|
|
108,851 |
|
|
|
970,891 |
|
2021 |
|
|
1,889,943 |
|
|
|
(726,843 |
) |
|
|
634,089 |
|
|
|
1,797,189 |
|
2020 |
|
|
1,274,209 |
|
|
|
(632,366 |
) |
|
|
349,153 |
|
|
|
990,996 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2023 |
|
|
2,306,789 |
|
|
|
(1,625,994 |
) |
|
|
(348,922 |
) |
|
|
331,873 |
|
2022 |
|
|
1,951,380 |
|
|
|
(1,238,352 |
) |
|
|
108,851 |
|
|
|
821,879 |
| The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2022 |
|
219,856 |
|
|
(159,850 |
) |
|
|
0 |
|
|
|
48,845 |
|
|
|
0 |
|
|
|
0 |
|
|
|
108,851 |
|
2021 |
|
699,890 |
|
|
(89,049 |
) |
|
|
0 |
|
|
|
23,248 |
|
|
|
0 |
|
|
|
0 |
|
|
|
634,089 |
|
2020 |
|
381,626 |
|
|
11,187 |
|
|
|
0 |
|
|
|
(43,660 |
) |
|
|
0 |
|
|
|
0 |
|
|
|
349,153 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2023 |
|
|
239,478 |
|
|
|
(298,292 |
) |
|
|
0 |
|
|
|
8,236 |
|
|
|
(298,344 |
) |
|
|
0 |
|
|
|
(348,922 |
) |
2022 |
|
|
219,856 |
|
|
|
(159,850 |
) |
|
|
0 |
|
|
|
48,845 |
|
|
|
0 |
|
|
|
0 |
|
|
|
108,851 |
|
|
|
|
|
Non-PEO NEO Average Total Compensation Amount |
|
|
$ 1,181,139
|
$ 1,161,724
|
$ 1,405,425
|
$ 1,023,409
|
Non-PEO NEO Average Compensation Actually Paid Amount |
|
|
$ 343,658
|
718,719
|
1,333,071
|
801,007
|
Adjustment to Non-PEO NEO Compensation Footnote |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Awards for Non -PEO
|
|
|
Equity Values for Non- PEO
|
|
|
Actually Paid to Non- PEO
|
|
|
|
|
|
|
2023 |
|
|
1,181,139 |
|
|
|
(657,440 |
) |
|
|
(180,041 |
) |
|
|
343,658 |
|
2022 |
|
|
1,161,724 |
|
|
|
(526,478 |
) |
|
|
83,473 |
|
|
|
718,719 |
|
2021 |
|
|
1,405,425 |
|
|
|
(629,160 |
) |
|
|
556,806 |
|
|
|
1,333,071 |
|
2020 |
|
|
1,023,409 |
|
|
|
(529,008 |
) |
|
|
306,606 |
|
|
|
801,007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year |
|
Fair Value
of Equity
Awards
Granted During
Year That
Remained
Unvested as of
Last Day of
Year for
($) |
|
|
Average
Change in Fair
Value from
Last Day of
Prior Year to
Last Day of
Year of
Unvested
Equity Awards
NEOs
($) |
|
|
Average
Vesting-Date
Fair Value of
Equity
Awards
Granted
During Year
that Vested
During Year
for
NEOs
($) |
|
|
Average Change
in Fair Value
from Last Day
of Prior Year to
Vesting Date of
Awards that
Vested During
Year for
($) |
|
|
Average Fair
Value at Last
Day of Prior
Year of
Equity
Awards
Forfeited
During Year
NEOs
($) |
|
|
Average Value
of Dividends
or Other
Earnings Paid
on Equity
Awards Not
Otherwise
Included for
NEOs
($) |
|
|
Total -
Average
Inclusion of
Equity
Values for
NEOs
($) |
|
|
|
|
|
|
|
|
|
2023 |
|
|
96,827 |
|
|
|
(111,716 |
) |
|
|
0 |
|
|
|
11,610 |
|
|
|
(176,762 |
) |
|
|
0 |
|
|
|
(180,041 |
) |
2022 |
|
|
156,771 |
|
|
|
(101,887 |
) |
|
|
0 |
|
|
|
28,589 |
|
|
|
0 |
|
|
|
0 |
|
|
|
83,473 |
|
2021 |
|
|
605,829 |
|
|
|
(76,579 |
) |
|
|
0 |
|
|
|
27,556 |
|
|
|
0 |
|
|
|
0 |
|
|
|
556,806 |
|
2020 |
|
|
333,411 |
|
|
|
10,833 |
|
|
|
0 |
|
|
|
(37,638 |
) |
|
|
0 |
|
|
|
0 |
|
|
|
306,606 |
|
|
|
|
|
Compensation Actually Paid vs. Total Shareholder Return |
|
|
Description of Relationship Between PEOs and Other NEO Compensation Actually Paid and Total Shareholder Return (“TSR”) The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our other NEOs, and the cumulative TSR over the four most recently completed fiscal years of the Company and the S&P 600 Health Care Equipment & Services Index.
|
|
|
|
Compensation Actually Paid vs. Net Income |
|
|
Description of Relationship Between PEOs and Other NEO Compensation Actually Paid and Net Income The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our other NEOs, and our Net Income during the four most recently completed fiscal years.
|
|
|
|
Compensation Actually Paid vs. Company Selected Measure |
|
|
Description of Relationship Between PEOs and Other NEO Compensation Actually Paid and Adjusted EBITDA The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our other NEOs, and our Adjusted EBITDA during the four most recently completed fiscal years.
|
|
|
|
Total Shareholder Return Vs Peer Group |
|
|
Description of Relationship Between PEOs and Other NEO Compensation Actually Paid and Total Shareholder Return (“TSR”) The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our other NEOs, and the cumulative TSR over the four most recently completed fiscal years of the Company and the S&P 600 Health Care Equipment & Services Index.
|
|
|
|
Total Shareholder Return Amount |
|
|
$ 42.92
|
104.3
|
112.27
|
102.85
|
Peer Group Total Shareholder Return Amount |
|
|
102.92
|
105.55
|
136.66
|
123.94
|
Net Income (Loss) |
|
|
$ 102,920
|
$ 15,867,000
|
$ 18,430,000
|
$ 14,246,000
|
Company Selected Measure Amount |
|
|
47,578,000
|
55,899,000
|
52,677,000
|
43,387,000
|
Measure:: 1 |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Non-GAAP Measure Description |
|
|
The Company selected Adjusted EBITDA as the most important financial measure it used to link Company performance to Compensation Actually Paid to our PEOs and Non-PEO NEOs in 2023. This performance measure may not have been the most important financial performance measure for years 2022, 2021 or 2020, and we may determine a different financial performance measure to be the most important financial performance measure in future years. See “Tabular List of Most Important Financial Performance Measures” below for the definition of Adjusted EBITDA.
|
|
|
|
J. Boyd Douglas [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
PEO Total Compensation Amount |
|
|
|
$ 1,600,378
|
$ 1,889,943
|
$ 1,274,209
|
PEO Actually Paid Compensation Amount |
|
|
$ 2,306,789
|
970,891
|
$ 1,797,189
|
$ 990,996
|
PEO Name |
|
J. Boyd Douglas
|
|
|
J. Boyd Douglas
|
J. Boyd Douglas
|
Christopher L. Flower [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
PEO Total Compensation Amount |
|
|
2,306,789
|
1,951,380
|
|
|
PEO Actually Paid Compensation Amount |
|
|
$ 331,873
|
821,879
|
|
|
PEO Name |
Christopher L. Fowler
|
|
Christopher L. Fowler
|
|
|
|
PEO | J. Boyd Douglas [Member] | Exclusion Of Stock Awards [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
|
(738,338)
|
$ (726,843)
|
$ (632,366)
|
PEO | J. Boyd Douglas [Member] | Inclusion Of Equity Values [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
|
108,851
|
634,089
|
349,153
|
PEO | J. Boyd Douglas [Member] | Year End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
|
219,856
|
699,890
|
381,626
|
PEO | J. Boyd Douglas [Member] | Change In Fair Value From Last Day Of Prior Year To Last Day Of Year Of Unvested Equity Awards [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
|
(159,850)
|
(89,049)
|
11,187
|
PEO | J. Boyd Douglas [Member] | Vesting Date Fair Value Of Equity Awards Granted During Year That Vested During Year [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
|
0
|
0
|
0
|
PEO | J. Boyd Douglas [Member] | Change In Fair Value From Last Day Of Prior Year To Vesting Date Of Unvested Equity Awards That Vested During Year [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
|
48,845
|
23,248
|
(43,660)
|
PEO | J. Boyd Douglas [Member] | Fair Value At Last Day Of Prior Year Of Equity Awards Forfeited During Year [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
|
0
|
0
|
0
|
PEO | J. Boyd Douglas [Member] | Value Of Dividends Or Other Earnings Paid On Equity Awards Not Otherwise Included [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
|
0
|
0
|
0
|
PEO | Christopher L. Flower [Member] | Exclusion Of Stock Awards [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
$ (1,625,994)
|
(1,238,352)
|
|
|
PEO | Christopher L. Flower [Member] | Inclusion Of Equity Values [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
(348,922)
|
108,851
|
|
|
PEO | Christopher L. Flower [Member] | Year End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
239,478
|
219,856
|
|
|
PEO | Christopher L. Flower [Member] | Change In Fair Value From Last Day Of Prior Year To Last Day Of Year Of Unvested Equity Awards [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
(298,292)
|
(159,850)
|
|
|
PEO | Christopher L. Flower [Member] | Vesting Date Fair Value Of Equity Awards Granted During Year That Vested During Year [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
0
|
0
|
|
|
PEO | Christopher L. Flower [Member] | Change In Fair Value From Last Day Of Prior Year To Vesting Date Of Unvested Equity Awards That Vested During Year [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
8,236
|
48,845
|
|
|
PEO | Christopher L. Flower [Member] | Fair Value At Last Day Of Prior Year Of Equity Awards Forfeited During Year [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
(298,344)
|
0
|
|
|
PEO | Christopher L. Flower [Member] | Value Of Dividends Or Other Earnings Paid On Equity Awards Not Otherwise Included [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
0
|
0
|
|
|
Non-PEO NEO | Exclusion Of Stock Awards [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
(657,440)
|
(526,478)
|
(629,160)
|
(529,008)
|
Non-PEO NEO | Inclusion Of Equity Values [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
(180,041)
|
83,473
|
556,806
|
306,606
|
Non-PEO NEO | Year End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
96,827
|
156,771
|
605,829
|
333,411
|
Non-PEO NEO | Change In Fair Value From Last Day Of Prior Year To Last Day Of Year Of Unvested Equity Awards [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
(111,716)
|
(101,887)
|
(76,579)
|
10,833
|
Non-PEO NEO | Vesting Date Fair Value Of Equity Awards Granted During Year That Vested During Year [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
0
|
0
|
0
|
0
|
Non-PEO NEO | Change In Fair Value From Last Day Of Prior Year To Vesting Date Of Unvested Equity Awards That Vested During Year [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
11,610
|
28,589
|
27,556
|
(37,638)
|
Non-PEO NEO | Fair Value At Last Day Of Prior Year Of Equity Awards Forfeited During Year [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
(176,762)
|
0
|
0
|
0
|
Non-PEO NEO | Value Of Dividends Or Other Earnings Paid On Equity Awards Not Otherwise Included [Member] |
|
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
|
Adjustment to Compensation, Amount |
|
|
$ 0
|
$ 0
|
$ 0
|
$ 0
|